与侵袭性胸腺瘤相关的肌危机成功地用ravulizumab治疗:一个病例系列
Akihiko Mitsutake1, Anna Suzuki1, Hiroyuki Murai2
1Department of Neurology, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Journal of the neurological sciences
|November 22, 2025
概括
拉武利祖马布在治疗常规护理不耐药的胸腺瘤相关性肌痛性肌痛危机 (TAMG) 中表现有前途. 这种补充抑制剂在小队列中证明了有效性和安全性,为具有挑战性的病例提供了潜在的新选择.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 骨髓灰质炎 (MG) 在骨髓灰质炎危机期间可能导致呼吸衰竭.
- 胸腺瘤相关的MG (TAMG),MG的一个子集,提出了治疗挑战,特别是在侵入性瘤.
- 拉武利祖马布是一种C5补充抑制剂,对通用MG有效,但其在TAMG危机中的作用尚不清楚.
研究的目的:
- 评估ravulizumab在侵袭性胸腺瘤 (Masaoka IVa阶段) 患者的肌危机治疗中的临床疗效和安全性.
- 评估ravulizumab在TAMG患者中对常规治疗不耐药的效用.
主要方法:
- 来自三个TAMG患者的临床数据的回顾性分析,这些患者患有侵袭性胸腺瘤,经历了肌危机.
- 所有患者都接受了ravulizumab的治疗.
主要成果:
- 所有患者在拉武利祖马布治疗后都呈现出临床改善.
- 两名患者实现了快速症状缓解,输出管和稳定.
- 一名患者因不完全反应需要额外的免疫治疗;没有报告任何不良事件.
结论:
- 拉武利祖马布可能是TAMG中耐火性肌危机的有效和安全的治疗选择.
- 需要进一步的研究来证实这些发现,并确定ravulizumab在TAMG管理中的作用.
关键词:
补充抑制是补充的抑制.侵袭性胸腺瘤是一种侵袭性胸腺瘤.骨髓灰质炎 (Myasthenia gravis) 是一个严重的疾病.我的肌性危机是什么?拉夫鲁兹马布的使用情况胸腺瘤相关的严重骨髓灰质炎.更多相关视频
相关概念视频
Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Myasthenia Gravis: Diagnostic Tests
1.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.9K
Myocarditis III: Medical Management
165
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
165
Pericarditis III: Medical Management
290
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
290
Myocarditis IV: Nursing Management
197
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
197
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K


